NIIMBL

NIIMBL announces 63 students for the 2024 NIIMBL eXperience

Retrieved on: 
Tuesday, April 30, 2024
University, Museum, Outline of health sciences, Experience, Sigma-Aldrich, Eli Lilly, North Carolina State University, Student, JIB, Santa Clara University, NIIMBL, Thomas Jefferson University, BTEC, Merck, University of Houston, Growth, Management

NEWARK, Del., April 30, 2024 /PRNewswire/ -- The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce 63 students from 41 academic institutions have been selected to take part in the 2024 NIIMBL eXperience, the largest cohort since the Program's launch in 2019.

Key Points: 
  • NEWARK, Del., April 30, 2024 /PRNewswire/ -- The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce 63 students from 41 academic institutions have been selected to take part in the 2024 NIIMBL eXperience, the largest cohort since the Program's launch in 2019.
  • The NIIMBL eXperience is a week-long, all-expenses-paid immersion program designed to introduce underrepresented groups including Black, Latinx, and Indigenous students completing their first or second year of college to career possibilities in the biopharmaceutical industry.
  • "The NIIMBL eXperience has been a cornerstone of our efforts to expand and diversify talent pipelines for the biopharmaceutical industry," said John Balchunas, NIIMBL Workforce Director.
  • Since 2019, the NIIMBL eXperience has served 80 students from 69 different academic institutions.

ChromaTan and Batavia Receive NIIMBL Grant to Integrate Column-Free Steady-State Continuous Elution Chromatography Into HIP-Vax® Manufacturing Platform for AAV

Retrieved on: 
Wednesday, April 10, 2024
Health, Health Technology, Genetics, Research, Science, Pharmaceutical, Biotechnology, Economics, Partnership, AAV, CDMO, NIIMBL, Commerce, Multimedia, Fine chemical

ChromaTan, a bioprocessing and biotools advanced biomanufacturing technology platform development company, is excited to announce an alliance with Batavia Biosciences, a leading contract development and manufacturing organization, for the development and integration of ChromaTan’s BioRMBTM continuous counter-current elution technology into Batavia’s AAV HIP-Vax® manufacturing platform.

Key Points: 
  • ChromaTan, a bioprocessing and biotools advanced biomanufacturing technology platform development company, is excited to announce an alliance with Batavia Biosciences, a leading contract development and manufacturing organization, for the development and integration of ChromaTan’s BioRMBTM continuous counter-current elution technology into Batavia’s AAV HIP-Vax® manufacturing platform.
  • This project further highlights ChromaTan’s and Batavia’s commitment to improving AAV manufacturing, while reducing manufacturing costs and optimizing the environmental footprint of biopharmaceuticals through process intensification.
  • Continuous counter-current elution chromatography has been shown to greatly contribute to the intensification of manufacturing processes for monoclonal antibodies.
  • As a leading CDMO, Batavia Biosciences aims to alleviate both the global shortage in rAAV manufacturing capacity and simultaneously reduce the cost of goods in the manufacturing process by integrating ChromaTan’s BioRMBTM – a novel column-free real moving bed continuous chromatography platform - into Batavia’s proprietary HIP-Vax® manufacturing platform.

NIIMBL hosts first-of-its-kind biopharma talent partnership event

Retrieved on: 
Wednesday, April 17, 2024
Ecosystem, Conference, NIIMBL, Acquisition, Workforce, Government, Economic development, Organization, Creative industries

Over 120 representatives from 79 organizations representing industry, academia, non-profits, and government are expected to attend the two-day event focused on strengthening biopharma talent acquisition efforts.

Key Points: 
  • Over 120 representatives from 79 organizations representing industry, academia, non-profits, and government are expected to attend the two-day event focused on strengthening biopharma talent acquisition efforts.
  • The event brings together talent acquisition personal, technical hiring managers, and community engagement leaders from industry with representatives from biopharma-centric universities, community colleges, non-profits, and career pathways intermediaries.
  • "We hope that by bringing the entire talent ecosystem together, we can help the industry solve talent shortages more collaboratively and pre-competitively."
  • The U.S. Biopharma Workforce Partnership Conference is part of NIIMBL's efforts to build national capacity to meet the talent acquisition, training, and workforce development needs of the biopharmaceutical manufacturing ecosystem.

NIIMBL Announces $10M for 8 New Biopharmaceutical Manufacturing Projects

Retrieved on: 
Tuesday, April 9, 2024
Project, University, Sigma-Aldrich, Pfizer, University of California, Agilent Technologies, NIIMBL, Workforce, Government, IPP, Janssen Pharmaceuticals, Organization, Fine chemical

The projects align with areas of need identified by NIIMBL and industry stakeholders.

Key Points: 
  • The projects align with areas of need identified by NIIMBL and industry stakeholders.
  • "We are excited to expand our diverse project portfolio with these innovative new projects," said Chris Roberts, Associate Institute Director.
  • Among the eight projects are two workforce development projects focused on data analytics training and strengthening the pipeline of neurodiverse talent.
  • NIIMBL is composed of nearly 200 member organizations from academia, industry, government, and non-profit organization with a common goal to advance biopharmaceutical manufacturing.

Dyadic Reports 2023 Full Year Results and Recent Company Progress

Retrieved on: 
Thursday, March 28, 2024
Cygnus, Enzyme, Rabies, SAHPRA, Biology, Sale, Innovation, Infection, Note, European, AVATAR, Therapy, Host cell protein, Vaccine, Analysis, Convertible, Research, Biotechnology, A-DNA, Massachusetts General Hospital, Partnership, Melamaravakkadu, Webcast, Primate, RNA, Biofuel, C1, Virology, SME, Safety, Nature Communications, Transferrin, Livestock, Global health, Manuscript, Food, Senior, NIIMBL, Antibody, Hospital, Antigen, Diagnosis, Health, Pithing, RBD, Phibro Animal Health, COVID-19, Dyadic, Messenger, Protein, Human

“In 2023, Dyadic achieved significant milestones in unlocking the potential of its microbial platforms.

Key Points: 
  • “In 2023, Dyadic achieved significant milestones in unlocking the potential of its microbial platforms.
  • We believe that we are well-positioned, both financially and scientifically, to execute our strategic plan with enhanced capabilities and resources.
  • For the year ended December 31, 2023, the Company received a total of approximately $1.3 million in connection with the sale of Alphazyme LLC.
  • Other Income: For the year ended December 31, 2023, the Company had a gain of approximately $1,018,000 from the sale of the Company’s equity interest in Alphazyme, LLC.

ChromaTan, Inc. Selected as a BLUE KNIGHT™ Company

Retrieved on: 
Tuesday, November 21, 2023
Research, Clinical Trials, Health Technology, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Safety, Plasma, Acceleration, Chemical engineering, ASPR, NIIMBL, FDA, Ecosystem, BLUE, Messenger, Pennsylvania State University, Chemical substance, Plasmid, NIH, HHS, Development, Bayard, Administration, The Blue Knight, Public, 3D printing, Fine chemical, Monoclonal antibody

ChromaTan, Inc., a bioprocess development company revolutionizing the 123-year-old traditional batch biopurification process through transformational next-generation biomanufacturing solutions, announced today that it has been selected as a BLUE KNIGHT™ company.

Key Points: 
  • ChromaTan, Inc., a bioprocess development company revolutionizing the 123-year-old traditional batch biopurification process through transformational next-generation biomanufacturing solutions, announced today that it has been selected as a BLUE KNIGHT™ company.
  • As a Blue Knight company, ChromaTan will gain access to the global JLABS ecosystem, a premier life science incubator program.
  • "We are excited to join JLABS as a Blue Knight company.
  • "I’m thrilled to see ChromaTan selected as a Blue Knight company.

Global Collaboration Illuminates Biopharma Manufacturing's Future: 207 Companies, 138 Vendors & 25 Countries Contribute - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 18, 2023
Biotechnology, Manufacturing, Other Manufacturing, Health, Pharmaceutical, Knowledge, University, Automation, Face, Research, Environment, Biopharmaceutical, Statistics, Annual report, Table, NIIMBL, Fine chemical, Marketing

To address these challenges head-on, the comprehensive report offers a 500+ page deep dive into the world of biomanufacturing operations.

Key Points: 
  • To address these challenges head-on, the comprehensive report offers a 500+ page deep dive into the world of biomanufacturing operations.
  • The " 20th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production " is the result of extensive research, with input from 207 biopharma companies, 138 industry vendors and suppliers, and representation from 25 countries.
  • This report isn't just informative; it's a global collaboration, bringing together experts and professionals from around the world to share their knowledge.
  • The "20th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production" is your indispensable companion on the path to excellence in biopharmaceutical manufacturing.

NIIMBL Is Now Accepting Applications for the 2024 NIIMBL eXperience Cohort After Awarding $500k to Expand Program

Retrieved on: 
Tuesday, October 17, 2023
Science, ACPHS, Hope, Courage, Student, Lewis & Clark College, Organization, Engineering, Experience, North Carolina State University, Geographic Locator Codes, Ecosystem, University, Patient, NIIMBL, Nursing, Tourism

The NIIMBL eXperience program is an all-expenses paid biopharmaceutical manufacturing immersion program for university and community college students who have completed their first or second year of study.

Key Points: 
  • The NIIMBL eXperience program is an all-expenses paid biopharmaceutical manufacturing immersion program for university and community college students who have completed their first or second year of study.
  • Specifically designed for Black, Latinx, and Indigenous students, the program strives to diversify the school-to-industry pipeline for the biopharmaceutical manufacturing industry.
  • In August 2023, NIIMBL issued a Request for Applications seeking proposals from NIIMBL members to expand the eXperience program across the United States.
  • Visit NIIMBL.org to learn more about the NIIMBL eXperience program and to apply for the 2024 cohort.

BioTools Innovator Names Limula 2023 Winner

Retrieved on: 
Friday, October 13, 2023
Biotechnology, Health Technology, Health, Medical Devices, Black Snow, Development, Sigma-Aldrich, AstraZeneca, Research Corporation, NIIMBL, Research, Standard BioTools, Eppendorf, Biomedical Advanced Research and Development Authority, RCT, Drug discovery, BARDA, Danaher, Prize, Patient, Feedback, Management, Pharmaceutical industry, Agilent Technologies, Genentech, Tolna limula

BioTools Innovator , the first-ever accelerator focused on life science tools companies, announced today that Limula (Lausanne, Switzerland) is the grand prize winner of the BioTools Innovator 2023 Final competition.

Key Points: 
  • BioTools Innovator , the first-ever accelerator focused on life science tools companies, announced today that Limula (Lausanne, Switzerland) is the grand prize winner of the BioTools Innovator 2023 Final competition.
  • The winning company was determined by a live audience vote Oct. 12 at the BioTools Innovator Capstone Event in Carlsbad, Calif.
    Limula, the winner of the $250,000 non-dilutive Grand Prize and the title of 2023 BioTools Innovator, offers an automated tool for scalable cell therapy manufacturing.
  • Nineteen companies were then selected to participate in the BioTools Innovator Accelerator, which prominently features best-in-class life science startups from around the world.
  • “Congratulations to Limula and all of the BioTools Innovator 2023 cohort companies.

NIIMBL Launches Viral Vector Program to Help Improve Patient Access to AAV Gene Therapy

Retrieved on: 
Tuesday, October 10, 2023
Vector (mathematics and physics), Hope, Government, Viral vector, University, Doctor of Philosophy, Ecosystem, Workforce, AAV, NIIMBL, Rare, University of Massachusetts Chan Medical School, Viral, Patient, Vaccine

"There are thousands of rare diseases, many of which could be candidates for AAV-based gene therapy.

Key Points: 
  • "There are thousands of rare diseases, many of which could be candidates for AAV-based gene therapy.
  • The initial structure of the Viral Vector Program will include:
    Additionally, a key component of the Viral Vector Program includes a parallel initiative in workforce development for key capabilities in AAV vector manufacturing and analytics.
  • NIIMBL will be hosting a webinar on the Viral Vector program on November 15, 2023.
  • To register for the webinar and to learn more about NIIMBL and the Viral Vector program, visit NIIMBL.org/ViralVector .